Solara Active Pharma Sciences Future Growth
Future criteria checks 4/6
Solara Active Pharma Sciences is forecast to grow earnings and revenue by 111% and 12.3% per annum respectively. EPS is expected to grow by 139% per annum. Return on equity is forecast to be 4.9% in 3 years.
Key information
111.0%
Earnings growth rate
139.0%
EPS growth rate
Pharmaceuticals earnings growth | 18.7% |
Revenue growth rate | 12.3% |
Future return on equity | 4.9% |
Analyst coverage | Low |
Last updated | 07 Mar 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2026 | 18,207 | 719 | N/A | N/A | 1 |
3/31/2025 | 17,070 | 293 | 1,024 | N/A | 1 |
3/31/2024 | 14,308 | -3,211 | 1,012 | N/A | 1 |
12/31/2023 | 14,069 | -3,083 | N/A | N/A | N/A |
9/30/2023 | 15,529 | -325 | 534 | 1,511 | N/A |
6/30/2023 | 14,661 | -253 | N/A | N/A | N/A |
3/31/2023 | 14,438 | -222 | 449 | 1,563 | N/A |
12/31/2022 | 14,240 | -241 | N/A | N/A | N/A |
9/30/2022 | 11,296 | -1,644 | -1,527 | -222 | N/A |
6/30/2022 | 11,928 | -1,247 | N/A | N/A | N/A |
3/31/2022 | 12,683 | -581 | -4,506 | -2,420 | N/A |
12/31/2021 | 13,517 | -34 | N/A | N/A | N/A |
9/30/2021 | 16,781 | 2,023 | -3,236 | -953 | N/A |
6/30/2021 | 16,740 | 2,293 | N/A | N/A | N/A |
3/31/2021 | 16,169 | 2,214 | -190 | 1,555 | N/A |
12/31/2020 | 14,694 | 1,826 | N/A | N/A | N/A |
9/30/2020 | 13,864 | 1,581 | 291 | 2,634 | N/A |
6/30/2020 | 13,400 | 1,304 | N/A | N/A | N/A |
3/31/2020 | 13,218 | 1,146 | -267 | 2,422 | N/A |
12/31/2019 | 14,103 | 1,231 | N/A | N/A | N/A |
9/30/2019 | 14,228 | 1,039 | 1,494 | 2,839 | N/A |
6/30/2019 | 14,140 | 845 | N/A | N/A | N/A |
3/31/2019 | 13,867 | 614 | 1,073 | 1,663 | N/A |
3/31/2018 | 5,210 | 60 | 145 | 492 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 541540 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (6.7%).
Earnings vs Market: 541540 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 541540 is expected to become profitable in the next 3 years.
Revenue vs Market: 541540's revenue (12.3% per year) is forecast to grow faster than the Indian market (10% per year).
High Growth Revenue: 541540's revenue (12.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 541540's Return on Equity is forecast to be low in 3 years time (4.9%).